Author

Natalie Fineman

Observed names: Fineman, Natalie, N Fineman, N. Fineman

Observed institutions: University of Dundee, University Hospitals Bristol NHS Foundation Trust, University of Bristol, University of Oxford, MRC Population Health Research Unit, University Hospitals Bristol and Weston NHS Foundation Trust, Medical Research Council

OpenAlex ID: A5089742214

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533

PDF

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

PDF

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

PDF

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines

2011 · Nick J. Andrews, Woolf T. Walker, et al. · Vaccine · 38

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

PDF

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2024 · RECOVERY Collaborative Group, Peter Sandercock, et al. · Nature Communications · 11

PDF

TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients

2024 · Huong D Nguyen, Fabienne Jouen, et al. · Lara D. Veeken · 7

PDF

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5

Anti-Sp4 and anti-CCAR1 autoantibodies in UK vs US patients with adult and juvenile-onset anti-TIF1γ-positive myositis

2024 · Fionnuala K McMorrow, Lucy R Wedderburn, et al. · Lara D. Veeken · 3

A test of a conceptual model of uncertainty, benefit and burden in children and young people with juvenile dermatomyositis

2026 · Polly Livermore, Klaudia H Kupiec, et al. · Rheumatology Advances in Practice

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases

PDF

Developing a new Paediatric Clinical Research Facility in collaboration with young people.

2024 · Fineman, Natalie, Pluess-Hall, Helen, et al.

Works count: 18

Citation count: 2,293

H-index: 11

I10-index: 11